{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:21:33Z","timestamp":1793226093692,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alimera Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic macular oedema [DMO] is a prevalent and sight-threatening condition among diabetic patients, which can cause irreversible blindness. Since angiogenesis and inflammation are two key elements in the etiopathogenesis of DMO, intravitreal injections of vascular endothelial growth factor inhibitors [anti-VEGF] and sustained released intravitreal corticosteroid implants are currently considered as treatments of choice. The introduction, 10 years ago, of the 0.19\u2009mg fluocinolone acetonide [FAc] implant for treating eyes with vision impairment associated with recurrent and persistent DMO represented an important advance. Since then, two randomized-control trials and many real-world studies have shown its good efficacy\/safety profile and the replicability of its treatment regimen. The FAc implant is, in general terms well tolerated, although it is associated with intraocular pressure-[IOP] and cataract-related adverse events [AEs]. Most IOP-related AEs are effectively controlled with ocular-hypotensive therapies. The objective of this paper is to review the role of FAc implant in the treatment of DMO over the 10 years since its launch, as well as its impact on clinical practice outcomes.<\/jats:p>","DOI":"10.1038\/s41433-025-03692-7","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:58:59Z","timestamp":1739937539000},"page":"1238-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["What have we learned from a decade treating patients with diabetic macular oedema with 0.19\u2009mg fluocinolone acetonide intravitreal implant?"],"prefix":"10.1038","volume":"39","author":[{"given":"Laurent","family":"Kodjikian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-0730","authenticated-orcid":false,"given":"Lilianne","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"3692_CR1","unstructured":"World Health Organization. Diabetes. [April 5, 2023]. Available in: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes Last accessed April, 2024."},{"key":"3692_CR2","unstructured":"Li JQ, Welchowski T, Schmid M, Letow J, Wolpers AC, et al. Retinal Diseases inEurope: Prevalence, incidence and healthcare needs. Available in: https:\/\/miloftalmica.it\/wp-content\/uploads\/2021\/07\/Euretina-Retinal-Diseases.pdf Last accessedApril, 2024."},{"key":"3692_CR3","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract."},{"key":"3692_CR4","doi-asserted-by":"publisher","first-page":"108072","DOI":"10.1016\/j.diabres.2020.108072","volume":"162","author":"R Williams","year":"2020","unstructured":"Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besan\u00e7on S, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020;162:108072.","journal-title":"Diabetes Res Clin Pract."},{"key":"3692_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580\u201391.","journal-title":"Ophthalmology."},{"key":"3692_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2045-3701-4-27","volume":"4","author":"X Zhang","year":"2014","unstructured":"Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.","journal-title":"Cell Biosci."},{"key":"3692_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375\u201394.","journal-title":"Ophthalmology."},{"key":"3692_CR8","doi-asserted-by":"publisher","first-page":"2156273","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016;2016:2156273.","journal-title":"J Diabetes Res"},{"key":"3692_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajpath.2016.08.022","volume":"187","author":"S Roy","year":"2017","unstructured":"Roy S, Kern TS, Song B, Stuebe C. Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy. Am J Pathol. 2017;187:9\u201319.","journal-title":"Am J Pathol."},{"key":"3692_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20\u201368.","journal-title":"Prog Retin Eye Res."},{"key":"3692_CR11","doi-asserted-by":"publisher","first-page":"831616","DOI":"10.3389\/fphys.2022.831616","volume":"13","author":"KL Bunch","year":"2022","unstructured":"Bunch KL, Abdelrahman AA, Caldwell RB, Caldwell RW. Novel Therapeutics for diabetic retinopathy and diabetic macular edema: a pathophysiologic perspective. Front Physiol. 2022;13:831616.","journal-title":"Front Physiol."},{"key":"3692_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10456-007-9074-0","volume":"10","author":"C Costa","year":"2007","unstructured":"Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007;10:149\u201366.","journal-title":"Angiogenesis"},{"key":"3692_CR13","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.4103\/ijo.IJO_1326_21","volume":"69","author":"A Sheemar","year":"2021","unstructured":"Sheemar A, Soni D, Takkar B, Basu S, Venkatesh P. Inflammatory mediators in diabetic retinopathy: deriving clinicopathological correlations for potential targeted therapy. Indian J Ophthalmol. 2021;69:3035\u201349.","journal-title":"Indian J Ophthalmol."},{"key":"3692_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica."},{"key":"3692_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/08820538.2016.1228388","volume":"32","author":"R Barham","year":"2017","unstructured":"Barham R, El Rami H, Sun JK, Silva PS. Evidence-based treatment of diabetic macular edema. Semin Ophthalmol. 2017;32:56\u201366.","journal-title":"Semin Ophthalmol."},{"key":"3692_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","volume":"19","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of diabetic macular edema. Curr Diab Rep. 2019;19:68.","journal-title":"Curr Diab Rep."},{"key":"3692_CR17","doi-asserted-by":"publisher","first-page":"107417","DOI":"10.1016\/j.jdiacomp.2019.107417","volume":"33","author":"RP Singh","year":"2019","unstructured":"Singh RP, Elman MJ, Singh SK, Fung AE, Stoilov I. Advances in the treatment of diabetic retinopathy. J Diabetes Complications 2019;33:107417.","journal-title":"J Diabetes Complications"},{"key":"3692_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583\u20137.","journal-title":"Ophthalmology."},{"key":"3692_CR19","unstructured":"Summary of product characteristics ILUVIEN 190 micrograms intravitreal implant in applicator. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/3061\/smpc#gref Last accessed April 12, 2024."},{"key":"3692_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626\u2013635.e2.","journal-title":"Ophthalmology."},{"key":"3692_CR21","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125\u201332.","journal-title":"Ophthalmology."},{"key":"3692_CR22","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ophtha.2014.04.019","volume":"121","author":"J Cunha-Vaz","year":"2014","unstructured":"Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121:1892\u2013903.","journal-title":"Ophthalmology."},{"key":"3692_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/eye.2016.301","volume":"31","author":"F Alfaqawi","year":"2017","unstructured":"Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant, for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye. 2017;31:650\u20136.","journal-title":"Eye."},{"key":"3692_CR24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/eye.2017.125","volume":"31","author":"C Bailey","year":"2017","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit Group. Real-world experience with 0.2\u2009\u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 2017;31:1707\u201315.","journal-title":"Eye."},{"key":"3692_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0726-1","volume":"18","author":"W Fusi-Rubiano","year":"2018","unstructured":"Fusi-Rubiano W, Mukherjee C, Lane M, Tsaloumas MD, Glover N, Kidess A, et al. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19\u2009mg Fluocinolone Acetonide intravitreal implant (Iluvien\u2122) at 2 years. BMC Ophthalmol. 2018;18:62.","journal-title":"BMC Ophthalmol."},{"key":"3692_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","volume":"8","author":"A Eaton","year":"2019","unstructured":"Eaton A, Koh SS, Jimenez J, Riemann CD. The USER Study: a chart review of patients receiving a 0.2 \u00b5g\/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8:51\u201362.","journal-title":"Ophthalmol Ther."},{"key":"3692_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40123-019-0197-3","volume":"8","author":"JF Young","year":"2019","unstructured":"Young JF, Walkden A, Stone A, Mahmood S. Clinical effectiveness of intravitreal Fluocinolone Acetonide (FAc) (ILUVIENTM) in patients with Diabetic Macular Oedema (DMO) refractory to prior therapy: the manchester experience. Ophthalmol Ther. 2019;8:477\u201384.","journal-title":"Ophthalmol Ther."},{"key":"3692_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1120672119834474","volume":"30","author":"AJ Augustin","year":"2020","unstructured":"Augustin AJ, Bopp S, Fechner M, Holz F, Sandner D, Winkgen AM, et al. Three-year results from the Retro-IDEAL study: real-world data from diabetic macular edema (DME) patients treated with ILUVIEN\u00ae (0.19mg fluocinolone acetonide implant). Eur J Ophthalmol. 2020;30:382\u201391.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","volume":"103","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. ILUVIEN Registry Safety Study (IRISS) Investigators Group. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103:1072\u20137.","journal-title":"Br J Ophthalmol."},{"key":"3692_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/bjophthalmol-2020-315984","volume":"105","author":"SE Mansour","year":"2021","unstructured":"Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, et al. Two-year interim safety results of the 0.2\u2009\u00b5g\/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021;105:414\u20139.","journal-title":"Br J Ophthalmol."},{"key":"3692_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/1120672119898414","volume":"31","author":"GD Panos","year":"2021","unstructured":"Panos GD, Arruti N, Patra S. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190\u2009\u03bcg (ILUVIEN\u00ae) in diabetic macular oedema in a multi-ethnic inner-city population. Eur J Ophthalmol. 2021;31:620\u20139.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR32","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.2147\/OPTH.S283561","volume":"15","author":"B Mushtaq","year":"2021","unstructured":"Mushtaq B, Bhatnagar A, Palmer H. Real-world outcomes in diabetic macular edema for the 0.2\u2009\u00b5g\/Day fluocinolone acetonide implant: case series from the Midlands, UK. Clin Ophthalmol. 2021;15:2935\u201343.","journal-title":"Clin Ophthalmol."},{"key":"3692_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41433-021-01542-w","volume":"36","author":"C Bailey","year":"2022","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit Group. Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study. Eye. 2022;36:1012\u20138.","journal-title":"Eye."},{"key":"3692_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/pharmaceutics13010072","volume":"13","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Baillif S, Creuzot-Garcher C, Delyfer MN, Matonti F, Weber M, et al. Real-world efficacy and safety of fluocinolone acetonide implant for diabetic macular edema: a systematic review. Pharmaceutics. 2021;13:72.","journal-title":"Pharmaceutics."},{"key":"3692_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics14040723","volume":"14","author":"T Mathis","year":"2022","unstructured":"Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, et al. Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real- life practice: the REALFAc study. Pharmaceutics. 2022;14:723.","journal-title":"Pharmaceutics."},{"key":"3692_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","volume":"129","author":"MA Singer","year":"2022","unstructured":"Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-Year Safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN Study. Ophthalmology. 2022;129:605\u201313.","journal-title":"Ophthalmology."},{"key":"3692_CR37","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1177\/1120672120982948","volume":"31","author":"AM Elbarky","year":"2021","unstructured":"Elbarky AM. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results. Eur J Ophthalmol. 2021;31:3196\u2013202.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84362-y","volume":"11","author":"M Fallico","year":"2021","unstructured":"Fallico M, Maugeri A, Lotery A, Longo A, Bonfiglio V, Russo A, et al. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience. Sci Rep. 2021;11:4800.","journal-title":"Sci Rep"},{"key":"3692_CR39","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/bjo-2022-321415","volume":"107","author":"R Khoramnia","year":"2023","unstructured":"Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L, et al. ILUVIEN Registry Safety Study (IRISS) Investigators Group. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol. 2023;107:1502\u20138.","journal-title":"Br J Ophthalmol."},{"key":"3692_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ajo.2022.09.017","volume":"248","author":"PT Merrill","year":"2023","unstructured":"Merrill PT, Holekamp N, Roth D, Kasper J, Grigorian R. PALADIN Study Group. The 0.19-mg fluocinolone acetonide intravitreal implant reduces treatment burden in diabetic macular edema. Am J Ophthalmol. 2023;248:16\u201323.","journal-title":"Am J Ophthalmol."},{"key":"3692_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.oret.2023.08.004","volume":"8","author":"DB Roth","year":"2024","unstructured":"Roth DB, Eichenbaum D, Malik D, Radcliffe NM, Cutino A, Small KW, et al. The 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: intraocular pressure-related effects over 36 Months. Ophthalmol Retina. 2024;8:49\u201354.","journal-title":"Ophthalmol Retina."},{"key":"3692_CR42","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1007\/s10792-023-02864-2","volume":"43","author":"JM Ruiz-Moreno","year":"2023","unstructured":"Ruiz-Moreno JM, Ad\u00e1n A, Lafuente M, Asencio Dur\u00e1n M, Arias Barquet L, Garc\u00eda Layana A, et al. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study. Int Ophthalmol. 2023;43:4639\u201349.","journal-title":"Int Ophthalmol."},{"key":"3692_CR43","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s40123-023-00749-2","volume":"12","author":"N Rousseau","year":"2023","unstructured":"Rousseau N, Lebreton O, Masse H, Maucourant Y, Pipelart V, Clement M, et al. Fluocinolone acetonide implant injected 1 month after dexamethasone implant for diabetic macular oedema: the ILUVI1MOIS Study. Ophthalmol Ther. 2023;12:2781\u201392.","journal-title":"Ophthalmol Ther."},{"key":"3692_CR44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/eye.2015.98","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye. 2015;29:1173\u201380.","journal-title":"Eye."},{"key":"3692_CR45","doi-asserted-by":"crossref","unstructured":"Parrish RK 2nd, Campochiaro PA, Pearson PA, Green K, Traverso CE; FAME Study Group. Characterization of Intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthal Surg Lasers Imaging Retina. 2016;47:426\u201335.","DOI":"10.3928\/23258160-20160419-05"},{"key":"3692_CR46","doi-asserted-by":"publisher","unstructured":"Capone L, Airaghi P, Aragona P, Castellino N, Cicinelli MV, Ciucci F, et al. Real-world experience with fluocinolone acetonide intravitreal implant in patients with diabetic macular edema. Eur J Ophthalmol. 2024:11206721241235266. https:\/\/doi.org\/10.1177\/11206721241235266.","DOI":"10.1177\/11206721241235266"},{"key":"3692_CR47","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40123-022-00504-z","volume":"11","author":"S Lebrize","year":"2022","unstructured":"Lebrize S, Arnould L, Bourredjem A, Busch C, Rehak M, Massin P, et al. Intraocular pressure changes after intravitreal fluocinolone acetonide implant: results from four European Countries. Ophthalmol Ther. 2022;11:1217\u201329.","journal-title":"Ophthalmol Ther."},{"key":"3692_CR48","doi-asserted-by":"publisher","unstructured":"Teixeira C, Pessoa B, Ru\u00e3o M, Sousa JPC, Penas S, Silva R, et al. ILUVIEN\u00ae in diabetic macular edema that persists or recurs despite treatment: Results from the Retina.pt\u00ae RIVER audit. Eur J Ophthalmol. 2023:11206721231217525. https:\/\/doi.org\/10.1177\/11206721231217525.","DOI":"10.1177\/11206721231217525"},{"key":"3692_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Diabetic retinopathy clinical research network. persistent macular thickening following intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136:257\u201369.","journal-title":"JAMA Ophthalmol."},{"key":"3692_CR50","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.2147\/OPTH.S320948","volume":"15","author":"P Udaondo","year":"2021","unstructured":"Udaondo P, Adan A, Arias-Barquet L, Ascaso FJ, Cabrera-L\u00f3pez F, Castro-Navarro V, et al. Challenges in diabetic macular edema management: an expert consensus report. Clin Ophthalmol. 2021;15:3183\u201395.","journal-title":"Clin Ophthalmol."},{"key":"3692_CR51","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064\u20131077.e35.","journal-title":"Ophthalmology."},{"key":"3692_CR52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325.","journal-title":"Ophthalmology."},{"key":"3692_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","volume":"134","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, et al. Diabetic retinopathy clinical research network. persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134:278\u201385.","journal-title":"JAMA Ophthalmol."},{"key":"3692_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I Data. Am J Ophthalmol. 2016;172:72\u201379.","journal-title":"Am J Ophthalmol."},{"key":"3692_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000497406","volume":"62","author":"P Massin","year":"2019","unstructured":"Massin P, Creuzot-Garcher C, Kodjikian L, Girmens JF, Delcourt C, Fajnkuchen F, et al. Real-world outcomes with Ranibizumab 0.5\u2009mg in patients with visual impairment due to diabetic macular Edema: 12-Month results from the 36-Month BOREAL-DME Study. Ophthalmic Res. 2019;62:101\u201310.","journal-title":"Ophthalmic Res."},{"key":"3692_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.oret.2017.10.016","volume":"2","author":"D Bellocq","year":"2018","unstructured":"Bellocq D, Akesbi J, Matonti F, Vartin C, Despreaux R, Comet A, et al. The Pattern of recurrence in diabetic macular edema treated by dexamethasone implant: the PREDIAMEX Study. Ophthalmol Retina. 2018;2:567\u201373.","journal-title":"Ophthalmol Retina."},{"key":"3692_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79288-w","volume":"11","author":"PJ Rodr\u00edguez-Vald\u00e9s","year":"2021","unstructured":"Rodr\u00edguez-Vald\u00e9s PJ, Rehak M, Zur D, Sala-Puigdollers A, Fraser-Bell S, Lupidi M, et al. GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study. Sci Rep. 2021;11:4738.","journal-title":"Sci Rep."},{"key":"3692_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","volume":"22","author":"AN Witmer","year":"2003","unstructured":"Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1\u201329.","journal-title":"Prog Retin Eye Res."},{"key":"3692_CR59","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/ijms23073645","volume":"23","author":"JL Wautier","year":"2022","unstructured":"Wautier JL, Wautier MP. Vascular permeability in diseases. Int J Mol Sci. 2022;23:3645.","journal-title":"Int J Mol Sci."},{"key":"3692_CR60","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/jcm8111841","volume":"8","author":"P Udaondo","year":"2019","unstructured":"Udaondo P, Hern\u00e1ndez C, Brians\u00f3-Llort L, Garc\u00eda-Delpech S, Sim\u00f3-Servat O, Sim\u00f3 R. Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study. J Clin Med. 2019;8:1841.","journal-title":"J Clin Med."},{"key":"3692_CR61","first-page":"CD007419","volume":"10","author":"G Virgili","year":"2018","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018;10:CD007419.","journal-title":"Cochrane Database Syst Rev"},{"key":"3692_CR62","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular Edema in the United States. Ophthalmol Retina 2018;2:1179\u201387.","journal-title":"Ophthalmol Retina"},{"key":"3692_CR63","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ. Real-world outcomes of Anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income Countries. Ophthalmol Ther. 2023;12:809\u201326.","journal-title":"Ophthalmol Ther."},{"key":"3692_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","volume":"128","author":"PB Burns","year":"2011","unstructured":"Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305\u201310.","journal-title":"Plast Reconstr Surg."},{"key":"3692_CR65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/jovr.jovr_279_18","volume":"14","author":"M Zarbin","year":"2019","unstructured":"Zarbin M. Real Life Outcomes vs. Clinical Trial Results. J Ophthalmic Vis Res. 2019;14:88\u201392.","journal-title":"J Ophthalmic Vis Res."},{"key":"3692_CR66","doi-asserted-by":"publisher","first-page":"8289253","DOI":"10.1155\/2018\/8289253","volume":"2018","author":"L Kodjikian","year":"2018","unstructured":"Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int. 2018;2018:8289253.","journal-title":"Biomed Res Int."},{"key":"3692_CR67","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","volume":"110","author":"H Funatsu","year":"2003","unstructured":"Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690\u20136.","journal-title":"Ophthalmology."},{"key":"3692_CR68","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ajo.2020.08.047","volume":"222","author":"JR Abraham","year":"2021","unstructured":"Abraham JR, Wykoff CC, Arepalli S, Lunasco L, Yu HJ, Hu M, et al. Aqueous Cytokine expression and higher order OCT biomarkers: assessment of the anatomic-biologic bridge in the IMAGINE DME study. Am J Ophthalmol. 2021;222:328\u201339.","journal-title":"Am J Ophthalmol."},{"key":"3692_CR69","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1755-3768.2009.01545.x","volume":"87","author":"TW Gardner","year":"2009","unstructured":"Gardner TW, Larsen M, Girach A, Zhi X. Protein Kinase C diabetic retinopathy Study (PKC-DRS2) Study Group. Diabetic macular oedema and visual loss: relationship to location, severity and duration. Acta Ophthalmol. 2009;87:709\u201313.","journal-title":"Acta Ophthalmol."},{"key":"3692_CR70","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Campbell J, Dugel PU, Holekamp NM, Kiss S, Loewenstein A, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye. 2020;34:480\u201390.","journal-title":"Eye."},{"key":"3692_CR71","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013\u201322.","journal-title":"Ophthalmology."},{"key":"3692_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00453-0","volume":"9","author":"RL Gurung","year":"2023","unstructured":"Gurung RL, FitzGerald LM, Liu E, McComish BJ, Kaidonis G, Ridge B, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. Int J Retina Vitreous. 2023;9:23.","journal-title":"Int J Retina Vitreous."},{"key":"3692_CR73","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203.","journal-title":"N Engl J Med."},{"key":"3692_CR74","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/OPTH.S236423","volume":"15","author":"D Veritti","year":"2021","unstructured":"Veritti D, Sarao V, Soppelsa V, Lanzetta P. Managing diabetic macular edema in clinical practice: systematic review and meta-analysis of current strategies and treatment options. Clin Ophthalmol. 2021;15:375\u201385.","journal-title":"Clin Ophthalmol."},{"key":"3692_CR75","first-page":"5047","volume":"22","author":"I Chatziralli","year":"2018","unstructured":"Chatziralli I. Editorial - Suboptimal response to intravitreal anti-VEGF treatment for patients with diabetic macular edema: is there any point in switching treatment? Eur Rev Med Pharmacol Sci. 2018;22:5047\u201350.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"3692_CR76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet."},{"key":"3692_CR77","doi-asserted-by":"publisher","first-page":"00933","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"S0161-6420","author":"TY Wong","year":"2023","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab Treat-and-extend for diabetic macular edema: two-year results from the randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2023;S0161-6420:00933\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026.","journal-title":"Ophthalmology."},{"key":"3692_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024;10:5. https:\/\/doi.org\/10.1186\/s40942-024-00525-9.","journal-title":"Int J Retina Vitreous."},{"key":"3692_CR79","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, et al. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024;260:70\u201383.","journal-title":"Am J Ophthalmol."},{"key":"3692_CR80","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","volume":"55","author":"C Busch","year":"2018","unstructured":"Busch C, Zur D, Fraser-Bell S, La\u00edns I, Santos AR, Lupidi M, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55:789\u201396.","journal-title":"Acta Diabetol."},{"key":"3692_CR81","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1120672119857511","volume":"29","author":"L Kodjikian","year":"2019","unstructured":"Kodjikian L, Bellocq D, Bandello F, Loewenstein A, Chakravarthy U, Koh A, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29:573\u201384.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR82","doi-asserted-by":"publisher","first-page":"e000696","DOI":"10.1136\/bmjophth-2020-000696","volume":"6","author":"L Downey","year":"2021","unstructured":"Downey L, Acharya N, Devonport H, Gale R, Habib M, Manjunath V, et al. Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021;6:e000696.","journal-title":"BMJ Open Ophthalmol."},{"key":"3692_CR83","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/pharmaceutics16091183","volume":"16","author":"L Sejournet","year":"2024","unstructured":"Sejournet L, Mathis T, Vermot-Desroches V, Serra R, Fenniri I, Denis P, et al. Efficacy and safety of fluocinolone acetonide implant in diabetic macular edema: practical guidelines from reference center. Pharmaceutics. 2024;16:1183.","journal-title":"Pharmaceutics."},{"key":"3692_CR84","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/bjophthalmol-2017-310242","volume":"101","author":"MV Cicinelli","year":"2017","unstructured":"Cicinelli MV, Cavalleri M, Querques L, Rabiolo A, Bandello F, Querques G. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol. 2017;101:1689\u201393.","journal-title":"Br J Ophthalmol."},{"key":"3692_CR85","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-019-00865-7","volume":"40","author":"G Demir","year":"2020","unstructured":"Demir G, Ozkaya A, Yuksel E, Erdogan G, Tunc U, Celal Ocal M, et al. Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response. Clin Drug Investig. 2020;40:119\u201328.","journal-title":"Clin Drug Investig."},{"key":"3692_CR86","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/1120672119848257","volume":"30","author":"A Hern\u00e1ndez Mart\u00ednez","year":"2020","unstructured":"Hern\u00e1ndez Mart\u00ednez A, Pereira Delgado E, Silva Silva G, Castellanos Mateos L, Lorente Pascual J, Lainez Villa J, et al. Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients? Eur J Ophthalmol. 2020;30:1091\u20138.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR87","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/1120672120929960","volume":"31","author":"J Ruiz-Medrano","year":"2021","unstructured":"Ruiz-Medrano J, Rodr\u00edguez-Leor R, Almaz\u00e1n E, Lugo F, Casado-Lopez E, Arias L, et al. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: early versus late switch. Eur J Ophthalmol. 2021;31:1135\u201345.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR88","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, Vi\u00e9 AL, Agard \u00c9, Bellocq D, et al. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension. Retina. 2017;37:1352\u20139.","journal-title":"Retina."},{"key":"3692_CR89","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00417-017-3773-z","volume":"256","author":"A Rezkallah","year":"2018","unstructured":"Rezkallah A, Kodjikian L, Malcl\u00e8s A, Dot C. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors. Graefes Arch Clin Exp Ophthalmol. 2018;256:219\u201320.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"Jan","key":"3692_CR90","doi-asserted-by":"publisher","first-page":"e0209997","DOI":"10.1371\/journal.pone.0209997","volume":"14","author":"J Zarranz-Ventura","year":"2019","unstructured":"Zarranz-Ventura J, Sala-Puigdollers A, Velazquez-Villoria D, Figueras-Roca M, Copete S, Distefano L, et al. Hospital Cl\u00ednic\u2014Hospital Vall de Hebron Intravitreal Dexamethasone Implant study group. Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world. PLoS ONE. 2019;14(Jan):e0209997.","journal-title":"PLoS ONE."},{"key":"3692_CR91","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41433-019-0616-7","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kuppermann BD, Bandello F, Lanzetta P, Zur D, Park SW, et al. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX- IOP study. Eye. 2020;34:1063\u20138.","journal-title":"Eye."},{"key":"3692_CR92","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1007\/s10792-023-02838-4","volume":"43","author":"Y Ayaz","year":"2023","unstructured":"Ayaz Y, Erkan Pota \u00c7, Ba\u015fol \u0130, Do\u011fan ME, T\u00fcrko\u011flu \u015een EB, et al. Anterior segment complications after dexamethasone implantations:real world data. Int Ophthalmol. 2023;43:4279\u201387.","journal-title":"Int Ophthalmol."},{"key":"3692_CR93","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin AM, Chaya CJ, Kahook MY, Wirostko BM. Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations. J Glaucoma. 2021;30:1019\u201326.","journal-title":"J Glaucoma."},{"key":"3692_CR94","unstructured":"Stoner AM, Lind JT, Gill Z, Seibold LK Anti-VEGF Injection IOP Elevations. EyeWiki\u00ae. American Academy of Ophthalmology. Updated July 24, 2022. Available in: https:\/\/eyewiki.aao.org\/Anti-VEGF_Injection_IOP_Elevations#Long-term_sustained_IOP_elevation Last accessed May, 2024."},{"key":"3692_CR95","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41433-021-01921-3","volume":"37","author":"MV Cicinelli","year":"2023","unstructured":"Cicinelli MV, Rabiolo A, Capone L, Di Biase C, Lattanzio R, Bandello F. Factors associated with the response to fluocinolone acetonide 0.19\u2009mg in diabetic macular oedema evaluated as the area-under-the-curve. Eye. 2023;37:242\u20138.","journal-title":"Eye."},{"key":"3692_CR96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40123-021-00427-1","volume":"11","author":"FJ Go\u00f1i","year":"2022","unstructured":"Go\u00f1i FJ, Barton K, Dias JA, Diestelhorst M, Garcia-Feijoo J, Hommer A, et al. Intravitreal Corticosteroid Implantation in Diabetic Macular Edema: Updated European Consensus Guidance on Monitoring and Managing Intraocular Pressure. Ophthalmol Ther. 2022;11:15\u201334.","journal-title":"Ophthalmol Ther."},{"key":"3692_CR97","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.jfo.2023.05.001","volume":"46","author":"C Dot","year":"2023","unstructured":"Dot C, Poli M, Aptel F, Labbe A, Kodjikian L, Baillif S, et al. Ocular hypertension and intravitreal steroids injections, update in 2023. French guidelines of the French glaucoma society and the French ophthalmology society. J Fr Ophtalmol. 2023;46:e249\u2013e256.","journal-title":"J Fr Ophtalmol."},{"key":"3692_CR98","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80\u201386.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"3692_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.17-22259","volume":"59","author":"SM Whitcup","year":"2018","unstructured":"Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018;59:1\u201312.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"3692_CR100","unstructured":"Authors nor listed. Comment traiter la migraine? [How to treat migraine?]. Available in: https:\/\/www.vidal.fr\/maladies\/douleurs-fievres\/migraine\/traitements-migraine.html Last accessed May, 2024."},{"key":"3692_CR101","doi-asserted-by":"publisher","unstructured":"Ndubuisi Okonkwo O, Akanbi T, Thelma Agweye C Current Management of Diabetic Macular Edema [Internet]. Diabetic Eye Disease - From Therapeutic Pipeline to the Real World. IntechOpen; 2022. Available from: https:\/\/doi.org\/10.5772\/intechopen.100157 Last accessed May 4, 2024.","DOI":"10.5772\/intechopen.100157"},{"key":"3692_CR102","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/jpm11101024","volume":"11","author":"TYY Lai","year":"2021","unstructured":"Lai TYY, Lai RYK. Association between Retinal thickness variability and visual acuity outcome during maintenance therapy using intravitreal anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. J Pers Med. 2021;11:1024.","journal-title":"J Pers Med."},{"key":"3692_CR103","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/24741264231201314","volume":"7","author":"VS Sheth","year":"2023","unstructured":"Sheth VS, Singer M, MacCumber M, Cutino A, Kasper J, Coughlin BA, et al. Long-term control of retinal thickness variability and vision following the 0.19mg Fluocinolone acetonide implant. J Vitreoretin Dis. 2023;7:490\u20137.","journal-title":"J Vitreoretin Dis."},{"key":"3692_CR104","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1177\/11206721221080288","volume":"32","author":"L Kodjikian","year":"2022","unstructured":"Kodjikian L, Bandello F, de Smet M, Dot C, Zarranz-Ventura J, Loewenstein A, et al. Fluocinolone acetonide implant in diabetic macular edema: International experts\u2019 panel consensus guidelines and treatment algorithm. Eur J Ophthalmol. 2022;32:1890\u20139.","journal-title":"Eur J Ophthalmol."},{"key":"3692_CR105","first-page":"1301","volume":"43","author":"VH Gonzalez","year":"2023","unstructured":"Gonzalez VH, Luo C, Almeida DRP, Cutino A, Coughlin B, Kasper J, et al. Better baseline vision leads to better outcomes after the 0.19-mg fluocinolone acetonide intravitreal implant in diabetic macular edema. Retina. 2023;43:1301\u20137.","journal-title":"Retina."},{"key":"3692_CR106","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1038\/s41433-022-02338-2","volume":"37","author":"E Dobler","year":"2023","unstructured":"Dobler E, Mohammed BR, Chavan R, Lip PL, Mitra A, Mushtaq B. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. Eye 2023;37:2310\u20135.","journal-title":"Eye"},{"key":"3692_CR107","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00592-019-01439-x","volume":"57","author":"M Rehak","year":"2020","unstructured":"Rehak M, Busch C, Unterlauft JD, Jochmann C, Wiedemann P. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Acta Diabetol. 2020;57:469\u201378.","journal-title":"Acta Diabetol."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03692-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:04:24Z","timestamp":1745996664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03692-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":107,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3692"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03692-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LK declares links with Abbvie, Bayer, Alimera, Roche, Novartis, Horus and Thea. Maged Habib received research grants, honoraria and travel grants from Alimera, Roche, Boehrigner-Ingelheim, and Bayer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}